Filter by:
  • Trial Status
  • Trial Phase
  • Age
  • Sex
  • Location

    location

    Clear All

About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

342,868 studies
in
216 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 08/05/2020.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 08/05/2020.
Displaying: 4,007 trials in your specialties ()
View trials across your selected specialties

Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Recurrent/Metastatic Squamous Cell Carcinoma of Head & Neck
View Full Trial
INTERVENTION

Drug: Tremelimumab, Drug: MEDI4736, Drug: MEDI4736 + Tremelimumab

Eligibility
  • Ages: 18 to 96 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Research Site, Baltimore, Maryland, United States

Brief Summary

The purpose of this study is to determine the efficacy and safety of investigational medical products (MEDI4736 monotherapy, tremelimumab monotherapy, and MEDI4736 + tremelimumab combination therapy) in the treatment of patients with recurrent or metastatic carcinoma of the head and neck who have progressed during or after treatment with a platinum containing regimen for recurrent/metastatic disease.

A Study of Atezolizumab in Advanced Solid Tumors

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Tumors
View Full Trial
INTERVENTION

Drug: Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Columbia University Medical Center, New York, New York, United States

Brief Summary

The primary efficacy objective for this study is to evaluate non-progression rate (NPR) at 18 weeks in participants with advanced solid tumors treated with atezolizumab, defined as the percentage of participants with complete response (CR), partial response (PR), or stable disease (SD) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1, or according to disease-specific criteria for prostate cancer and malignant pleural mesothelioma.

Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcomas

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Myxoid Liposarcoma of Soft Tissue
View Full Trial
INTERVENTION

Radiation: dose reduction of preoperative radiotherapy in MLS

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Radboud umc, NIjmegen, Netherlands

Brief Summary

To study the feasibility of reducing the dose of preoperative radiotherapy in MLS (Myxoid Liposarcomas) from 50 Gy to 36 Gy while maintaining comparable clinicopathological responses.

Long Term Safety and Efficacy of Ralinepag in Pulmonary Arterial Hypertension

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Pulmonary Arterial Hypertension
View Full Trial
INTERVENTION

Drug: Ralinepag

Eligibility
  • Ages: 18 to 75 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

University of Alabama at Birmingham, Birmingham, Alabama, United States

Brief Summary

This study is an open-label extension study to determine the long-term safety and tolerability of APD811 in patients with WHO Group 1 PAH who have completed the Phase 2 study, APD811-003. Patients must have completed the APD811-003 study and must meet eligibility criteria for APD811-007.

Phase 1/2a Study of BAL101553 as 48-hour Infusions in Patients With Advanced Solid Tumors or Recurrent Glioblastoma

  • Status
    Active, not recruiting
  • Phase
    Phase 1 Phase 2
  • Condition
    Neoplasms
View Full Trial
INTERVENTION

Drug: BAL101553, Drug: BAL101553 at MTD

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Oncology Institute of Southern Switzerland; Ospedale Regionale San Giovanni Bellinzona e Valli, Bellinzona, Switzerland

Brief Summary

Single-agent, open-label, multi-center sequential dose escalation and expansion study of BAL101553, administered as an intravenous (IV) infusion over 48 hours to adults with advanced or recurrent solid tumors or recurrent glioblastoma.

Ledipasvir+Sofosbuvir and Sofosbuvir+Velpatasvir for Pts With Indolent Bcell Lymphoma Associated With HCV Infection

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Hepatitis C, Indolent B-cell Lymphoma
View Full Trial
INTERVENTION

Drug: Ledipasvir+Sofosbuvir, Drug: Sofosbuvir+Velpatasvir

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Ospedale San Raffaele Ematologia, Milano, Italy

Brief Summary

This is a non-randomized, a single arm, phase II multicentre study of sofosbuvir plus ledipasvir (genotype 1 and 4) or sofosbuvir plus velpatasvir (genotype 2 and 3) for patients with hepatitis C virus-associated indolent B-cell lymphomas (HCV-RNA positive).

Pharmaco-immunological Study of Interferon-alpha and Metronomic Cyclophosphamide Association in Neuroendocrine Tumors

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Neuroendocrine Tumors
View Full Trial
INTERVENTION

Drug: Metronomic cyclophosphamide, Drug: Interferon-alpha

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Centre Hospitalier Universitaire de Besançon, Besancon, France

Brief Summary

This study will evaluate the potential immunomodulatory synergy of the association of metronomic cyclophosphamide (CMC) and interferon-alpha (IFN-alpha).

Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors or Glioblastoma or High-grade Glioma

  • Status
    Active, not recruiting
  • Phase
    Phase 1 Phase 2
  • Condition
    Neoplasms
View Full Trial
INTERVENTION

Drug: Oral daily administration of BAL101553

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

Brief Summary

First in human, open-label, sequential dose escalation and expansion study of oral BAL101553 in adult patients with advanced solid tumors and adult patients with recurrent or progressive glioblastoma or high-grade glioma.

Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Extensive Stage Lung Small Cell Carcinoma, Recurrent Lung Small C...
View Full Trial
INTERVENTION

Drug: Carboplatin, Drug: Cisplatin, Drug: Etoposide, Biological: Nivolumab

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States

Brief Summary

This randomized phase II clinical trial studies whether the addition of nivolumab to cisplatin (or carboplatin) and etoposide will improve outcomes when treating patients with extensive stage small cell lung cancer. Drugs used in chemotherapy such as cisplatin, carboplatin, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cisplatin/carboplatin and etoposide together with nivolumab may work better in treating patients with extensive stage small cell lung cancer.

Pembrolizumab Plus Amurubicin in Patients With Refractory Small-cell Lung Cancer

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Small Cell Lung Cancer Extensive Stage
View Full Trial
INTERVENTION

Drug: Pembrolizumab plus amurubicin

Eligibility
  • Ages: 20 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Wakayama Medical University, Wakayama, Japan

Brief Summary

To explore the overall response rate (ORR) per RECIST 1.1 as assessed by investigators in subjects with refractory small cell lung cancer treated with pembrolizumab (Pembro) plus amurubicin (AMR).